Drug Approval | January 05, 2025
CDSCO approves Wockhardt’s Mignaf for treatment of community acquired bacterial pneumonia
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Wockhardt plans to launch Miqnaf in the Indian market in coming few months
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
SynerK owns intellectual property rights of SNK-2726, which is currently in the IND filing preparation stage
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
Subscribe To Our Newsletter & Stay Updated
